Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ganciclovir ophthalmic - Laboratoires Thea

Next Previous
Drug Profile

Ganciclovir ophthalmic - Laboratoires Thea

Alternative Names: Ganciclovir ophthalmic gel 0.15%; ST-605; Virgan; Zirgan

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Laboratoires Thea
  • Developer Laboratoires Thea; Ms Science; Sirion Therapeutics
  • Class Antineoplastics; Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ocular herpes simplex
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ocular herpes simplex
  • Phase II Cytomegalovirus infections; Dendritic keratitis

Most Recent Events

  • 23 Feb 2021 Ganciclovir ophthalmic is still in phase II trials for Dendritic keratitis in Japan (Ophthalmic) (JapicCTI-183901)
  • 08 Dec 2020 Northwestern University terminates phase II trial in Herpes zoster keratitis in USA due to difficulties meeting enrollment goal (NCT02382588)
  • 01 Apr 2018 Phase-II clinical trials in Dendritic keratitis in Japan (Ophthalmic) (JapicCTI-183901)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top